858 Therapeutics

858 Therapeutics is a biotechnology and drug discovery company located in San Diego, California. They are focused on developing novel small molecule drugs targeting oncology, neuroscience, and cardiovascular disease. The company has a strong team of seasoned professionals with a track record of success in drug development. Their research leverages expertise in structure-based drug discovery and translational research, aiming to create differentiated drug candidates.

858 Therapeutics' pipeline is focused on important nodes in cancer biology, including DNA damage repair, innate immunity, and RNA epigenetics. They are currently advancing a portfolio of small molecule drugs that address these areas, and are expected to begin phase 1 trials for their PARG program in 2024. 858 Therapeutics is backed by prominent venture capital firms, including Versant Ventures, NEA, Cormorant Asset Management, and Logos Capital.

858 Therapeutics is a biotechnology company focused on discovering innovative small molecule drugs that target novel therapeutic pathways in oncology, neuroscience, and cardiovascular disease. Their mission is to develop treatments for cancers that are resistant to current therapies, utilizing expertise in synthetic lethality, innate immunity, and RNA modulation to create differentiated drug candidates.

858 Therapeutics fosters a collaborative and innovative culture that prioritizes scientific excellence. The company draws upon its veteran team's expertise in drug discovery and development, creating an environment where scientists are dedicated to advancing novel therapies. The company's commitment to research and its location in the San Diego biotech hub encourage a culture that values scientific curiosity, knowledge sharing, and the pursuit of groundbreaking discoveries.